{"schema_version":"secwatch.filing_event.v1","accession":"0001703057-26-000044","form_type":"8-K","ticker":"ABCL","cik":"0001703057","company_name":"AbCellera Biologics Inc.","filed_at":"2026-08-05T20:18:02+00:00","discovered_at":"2026-08-05T20:19:02.170553+00:00","generated_at":"2026-08-05T20:19:39.666643+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"AbCellera Q2 net loss widens to $55.4M; revenue drops to $4.1M; new Jazz, Vertex deals","bullets":["Net loss of $55.4M ($0.18/sh) vs $34.7M ($0.12/sh) in Q2 2025; revenue $4.1M vs $17.1M.","Ended quarter with >$565M cash and marketable securities; total liquidity >$675M.","Announced collaborations with Jazz ($84M upfront) and Vertex ($28M upfront) for T-cell engagers.","ABCL635 Phase 2 top-line data expected in August 2026; ABCL575 Phase 1 data expected Q4 2026.","Partner programs progressing: 35 (down from 44 at Dec 2025); 12 molecules in clinic."],"urls":{"canonical":"https://secwatch.observer/filing/0001703057-26-000044","json":"https://secwatch.observer/filing/0001703057-26-000044.json","markdown":"https://secwatch.observer/filing/0001703057-26-000044.md","text":"https://secwatch.observer/filing/0001703057-26-000044.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1703057/000170305726000044/0001703057-26-000044-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1703057/000170305726000044/abcl-20260805.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-05T20:19:39.666643+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}